APREPITANT TEVA 125 mg, hard capsule and aprepitant teva 80 mg, hard capsule capsule
Active ingredients: Aprepitant
Commercialized according to BDPMANSM noticeDispensing in France: Prescription only
Hard capsulecapsuleorale
Supply disruption
Package details
Original BDPM fields are shown in French.
- Official name
- APREPITANT TEVA 125 mg, gélule et APREPITANT TEVA 80 mg, gélule
- Pharmaceutical form
- gélule et gélule
- Route of administration
- orale
- Presentation description
- plaquette(s) polyamide aluminium PVC de 1 gélule blanche et rose et de 2 gélule(s) blanches
- Marketing authorisation holder
- TEVA (PAYS-BAS)
- Reimbursement according to BDPM
- 65%
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 16 May 2019
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66503721CIP73015106CIP133400930151068Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| APRÉPITANTgélule (125 mg) | 125 mg · une gélule | SA |
| APRÉPITANTgélule (80 mg) | 80 mg · une gélule | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.